Butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Intently. Coadministration of CYP3A4 inducers may possibly decrease sufentanil concentrations and efficacy, possibly precipitating withdrawal syndrome in patients which have created physical dependence to sufentanil. Discontinuation of concomitantly made us... https://cassq135oqr0.verybigblog.com/profile